Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran.
Inflammopharmacology. 2024 Oct;32(5):2987-3005. doi: 10.1007/s10787-024-01523-x. Epub 2024 Aug 21.
Epilepsy ranks among the most prevalent neurological conditions worldwide. Cannabidiol (CBD) has received authorization for epilepsy treatment, yet utilizing CBD is linked to a variety of adverse events (AEs). This umbrella review aims to explore risk and frequency of AEs in epilepsy patients undergoing treatment with CBD.
International electronic databases comprising Scopus, PubMed, and Web of Science were extensively searched from the most ancient data accessible until May 2024. In line with fundamental principle of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA), this umbrella review was executed. RStudio software version 2023.03.1 along with R software 4.3.2 was used for our statistical analyses.
Thirteen meta-analyses and systematic reviews were included. CBD use in epileptic patients compared to controls can be meaningfully linked with 10.87% becoming seizure-free (RD: 10.87%, 95%CI: 2.39%, 19.34%; I = 80%). Compared to controls, a meaningful 73% increase in 50% or greater reduction in seizure frequency was observed (RR: 1.73, 95%CI: 1.47, 2.03; I = 0%). In epileptic individuals who using CBD with the dosage of 20 mg/kg/d, a higher incidence of treatment withdrawal was detected (RR: 4.39, 95%CI: 2.46, 7.83; I = 0%).
In this umbrella review of meta-analyses and systematic reviews, CBD use in epileptic patients was linked to an increased risk of ample AEs. Further research, specifically targeting various epilepsy categories, is essential to fully understand the effectiveness and potential side effects of CBD across different epilepsy forms.
癫痫是全球最常见的神经疾病之一。大麻二酚（CBD）已被授权用于治疗癫痫，但使用 CBD 与多种不良事件（AE）有关。本伞式综述旨在探讨接受 CBD 治疗的癫痫患者发生 AE 的风险和频率。
全面检索了 Scopus、PubMed 和 Web of Science 三个国际电子数据库，检索时间从可获得的最早数据截止到 2024 年 5 月。本伞式综述符合系统评价和荟萃分析的首选报告项目（PRISMA）基本原则。使用 RStudio 软件版本 2023.03.1 和 R 软件 4.3.2 进行统计分析。
纳入了 13 项荟萃分析和系统评价。与对照组相比，癫痫患者使用 CBD 可显著使 10.87%的患者无癫痫发作（RD：10.87%，95%CI：2.39%，19.34%；I²=80%）。与对照组相比，观察到癫痫患者使用 CBD 后癫痫发作频率减少 50%或更多的比例显著增加了 73%（RR：1.73，95%CI：1.47，2.03；I²=0%）。在使用 CBD 剂量为 20mg/kg/d 的癫痫患者中，发现治疗停药的发生率更高（RR：4.39，95%CI：2.46，7.83；I²=0%）。
本荟萃分析和系统评价的伞式综述表明，癫痫患者使用 CBD 会增加发生大量 AE 的风险。需要进一步研究，特别是针对各种癫痫类别，以充分了解 CBD 在不同癫痫形式下的有效性和潜在副作用。
